TrialBMC cancer2020

Early prediction of pathologic response to neoadjuvant treatment of breast cancer: use of a cell-loss metric based on serum thymidine kinase 1 and tumour volume.

Bernhard TribukaitPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.